Monitoring temperatures across the cold chain
24/7 checks possible with Comark RF500 system
Correct storage and transportation temperatures are fundamental to maintaining the quality of medicines. Even so, during 2005/6 (the latest figures available), MHRA inspectors found that nearly 33% of all major deficiencies concerned failures with the control and monitoring of temperatures, and 17% related directly to medicines.
According to UK supplier of automated temperature monitoring equipment, Comark, resistance to temperature monitoring by some sectors of the industry comes from the perceived inflexibility of traditional hard-wired systems. There are also concerns about the reliability of newer wireless developments. However, the Hitchin, Hertfordshire-based firm says new mesh networking and bi-directional technology is providing a strong argument for taking another look at the latest generation of wireless systems.
Comark’s RF500, for example, provides automatic 24/7 monitoring of critical temperature points within a process or across an entire site. A central Gateway unit collects the data for analysis and gives alarm notification by email, voice or SMS if temperature and/or RH levels move outside preset limits. The RF500 maintains a complete history of temperature and/or humidity levels.
A UK Healthcare Trust is using RF500 systems to provide 24/7 monitoring of 180 critical locations, including blood fridges in pathology labs and blood banks across four hospital sites. Previous methods involved a network of chart recorders, data loggers and manual checks.
Comark has also broadened the applications of the RF500 to cover goods in transit. A transmitter placed in a vehicle will continuously monitor temperature and automatically transmit the data to the Gateway unit as soon as the transmitter returns within range.
A wholesaler with multiple UK locations and a fleet of delivery vehicles engaged in distributing pharmaceuticals and medicines to a network of high street pharmacies has ordered a system.
You may also like
Manufacturing
Domino demonstrates an integrated approach to next-generation coding at Interpack 2026
Read moreAt Interpack 2026, Domino Printing Sciences (Domino) will focus on the key challenges manufacturers face as variable data printing enters a new era shaped by 2D codes, intelligent automation, sustainability, and growing traceability demands. Domino specialists will be available throughout the show to highlight integrated solutions designed to work together on the factory floor – developed in collaboration with key industry partners to help to reduce complexity, risk, and operational friction for manufacturers
Trending Articles
You may also like
Manufacturing
Domino demonstrates an integrated approach to next-generation coding at Interpack 2026
At Interpack 2026, Domino Printing Sciences (Domino) will focus on the key challenges manufacturers face as variable data printing enters a new era shaped by 2D codes, intelligent automation, sustainability, and growing traceability demands. Domino specialists will be available throughout the show to highlight integrated solutions designed to work together on the factory floor – developed in collaboration with key industry partners to help to reduce complexity, risk, and operational friction for manufacturers
Manufacturing
Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target
BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Manufacturing
Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair
Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model
Manufacturing
BioNTech to cut up to 1860 jobs and end COVID vaccine production in Germany
The German biotech has announced it will cease production at its manufacturing sites in Germany and Singapore in its Q1 earnings report, cutting up to 22% of its workforce in the process as it pivots from COVID-19 vaccines to oncology